Can DCE-MRI Explain the Heterogeneity in Radiopeptide Uptake Imaged by SPECT in a Pancreatic Neuroendocrine Tumor Model?

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Bol, Karin ^a   Haeck, Joost C ^a   Groen, Harald C ^a   Niessen, Wiro J ^a,b   Bernsen, Monique R ^a   de Jong, Marion ^a   Veenland, Jifke F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PENTETREOTIDE IN 111;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL PERMEABILITY; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; IMAGE ANALYSIS; ISOTOPE LABELING; MALE; MAXIMUM ENHANCEMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ONCOLOGICAL PARAMETERS; PANCREATIC NEUROENDOCRINE TUMOR; PARAMETERS; QUANTITATIVE ANALYSIS; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR PERFUSION; VESSEL DENSITY;

ANIMALS; CONTRAST MEDIA; INDIUM RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREAS; PANCREATIC NEOPLASMS; PENTETIC ACID; RATS; RATS, INBRED LEW; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84885100296     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077076     Document Type: Article

References (32)

1. de Herder WW, Kwekkeboom DJ, Feelders RA, van Aken MO, Lamberts SW, et al. (2006) Somatostatin receptor imaging for neuroendocrine tumors. Pituitary 9: 243-248. doi:10.1007/s11102-006-0270-5. PubMed: 17001462.
2. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, et al. (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716-731. PubMed: 8404961.
3. Patel YC, (1990) Somatostatin-receptor imaging for the detection of tumors. N Engl J Med 323: 1274-1276. doi:10.1056/NEJM199011013231811. PubMed: 2170841.
4. Rufini V, Calcagni ML, Baum RP, (2006) Imaging of neuroendocrine tumors. Semin Nucl Med 36: 228-247. doi:10.1053/j.semnuclmed.2006.03.007. PubMed: 16762613.
5. de Jong M, Kwekkeboom D, Valkema R, Krenning EP, (2003) Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 30: 463-469. doi:10.1007/s00259-002-1107-8. PubMed: 12569416.
6. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP, (2007) Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 21: 111-129. doi:10.1016/j.beem.2007.01.007. PubMed: 17382268.
7. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, et al. (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26: 2124-2130. doi:10.1200/JCO.2007.15.2553. PubMed: 18445841.
8. Reubi JC, Mäcke HR, Krenning EP, (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46 (Suppl 1):: 67S-75S. PubMed: 15653654.
9. Bodei L, Pepe G, Paganelli G, (2010) Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci 14: 347-351. PubMed: 20496546.
10. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ, (2005) Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14: 1766-1773. doi:10.1158/1055-9965.EPI-05-0120. PubMed: 16030115.
11. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM, (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19: 1727-1733. doi:10.1093/annonc/mdn351. PubMed: 18515795.
12. Miyazaki K, Orton MR, Davidson RL, d'Arcy JA, Lewington V, et al. (2012) Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response. Radiology 263: 139-148. doi:10.1148/radiol.12110770. PubMed: 22344403.
13. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, et al. (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46 (Suppl 1):: 62S-66S. PubMed: 15653653.
14. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ, (2007) Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 46: 723-734. doi:10.1080/02841860701441848. PubMed: 17653893.
15. Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ, (2005) Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 80: 502-506. doi:10.4065/80.4.502. PubMed: 15819288.
16. Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, et al. (2005) 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 32: 1288-1295. doi:10.1007/s00259-005-1877-x. PubMed: 16021448.
17. Heisen M, Fan X, Buurman J, van Riel NA, Karczmar GS, et al. (2010) The influence of temporal resolution in determining pharmacokinetic parameters from DCE-MRI data. Magn Reson Med 63: 811-816. doi:10.1002/mrm.22171. PubMed: 20187187.
18. Klein S, Staring M, Murphy K, Viergever MA, Pluim JP, (2010) elastix: a toolbox for intensity-based medical image registration. IEEE Trans Med Imaging 29: 196-205. doi:10.1109/TMI.2009.2035616. PubMed: 19923044.
19. Parker GJ, Suckling J, Tanner SF, Padhani AR, Revell PB, et al. (1997) Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 7: 564-574. doi:10.1002/jmri.1880070318. PubMed: 9170043.
20. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, et al. (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10: 223-232. doi:10.1002/(SICI)1522-2586(199909)10:3. PubMed: 10508281.
21. McGrath DM, Bradley DP, Tessier JL, Lacey T, Taylor CJ, et al. (2009) Comparison of model-based arterial input functions for dynamic contrast-enhanced MRI in tumor bearing rats. Magn Reson Med 61: 1173-1184. doi:10.1002/mrm.21959. PubMed: 19253360.
22. Buckley DL, (2002) Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 47: 601-606. doi:10.1002/mrm.10080. PubMed: 11870848.
23. Asselin MC, O'Connor JP, Boellaard R, Thacker NA, Jackson A, (2012) Quantifying heterogeneity in human tumours using MRI and PET. Eur J Cancer 48: 447-455. doi:10.1016/j.ejca.2011.12.025. PubMed: 22265426.
24. Alic L, van Vliet M, van Dijke CF, Eggermont AM, Veenland JF, et al. (2011) Heterogeneity in DCE-MRI parametric maps: a biomarker for treatment response? Phys Med Biol 56: 1601-1616. doi:10.1088/0031-9155/56/6/006. PubMed: 21335648.
25. Jansen JF, Schöder H, Lee NY, Stambuk HE, Wang Y, et al. (2012) Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Int J Radiat Oncol Biol Phys 82: 299-307. doi:10.1016/j.ijrobp.2010.11.022. PubMed: 21236594.
26. O'Connor JP, Rose CJ, Jackson A, Watson Y, Cheung S, et al. (2011) DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer 105: 139-145. doi:10.1038/bjc.2011.191. PubMed: 21673686.
27. Lee JD, Kim DI, Lee JT, Chang JW, Park CY, (1995) Indium-111-pentetreotide imaging in intra-axial brain tumors: comparison with thallium-201 SPECT and MRI. J Nucl Med 36: 537-541. PubMed: 7699438.
28. Metz S, Ganter C, Lorenzen S, van Marwick S, Herrmann K, et al. (2010) Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med 51: 1691-1698. doi:10.2967/jnumed.110.077719. PubMed: 20956471.
29. Hansen AE, Kristensen AT, Law I, McEvoy FJ, Kjaer A, et al. (2012) Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiother Oncol 102: 424-428. doi:10.1016/j.radonc.2011.10.021. PubMed: 22119225.
30. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, et al. (1995) Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 36: 623-627. PubMed: 7699456.
31. de Jong M, Breeman WA, Bernard BF, van Gameren A, de Bruin E, et al. (1999) Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med 26: 693-698. doi:10.1007/s002590050439. PubMed: 10398816.
32. Melancon MP, Elliott AM, Shetty A, Huang Q, Stafford RJ, et al. (2011) Near-infrared light modulated photothermal effect increases vascular perfusion and enhances polymeric drug delivery. J Control Release 156: 265-272. doi:10.1016/j.jconrel.2011.06.030. PubMed: 21763373.